Literature DB >> 15824202

Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy.

Anna Woo1, William G Williams, Richard Choi, E Douglas Wigle, Evelyn Rozenblyum, Katie Fedwick, Samuel Siu, Anthony Ralph-Edwards, Harry Rakowski.   

Abstract

BACKGROUND: Surgical myectomy has been the standard treatment for patients with drug-refractory obstructive hypertrophic cardiomyopathy. The clinical and echocardiographic predictors of long-term survival and freedom from cardiovascular morbidity after myectomy have been unclear. METHODS AND
RESULTS: We studied a consecutive cohort of 338 adult patients (age at operation 47+/-14 [range 18 to 77] years, 60% male) who underwent myectomy at our institution. Preoperative resting left ventricular outflow tract (LVOT) gradient was 66+/-32 mm Hg (range 5 to 158 mm Hg). Early postoperative mortality was 1.5% (5 deaths): 4 deaths occurred between 1978 and 1992, and 1 death occurred between 1993 and 2002. During long-term follow-up, 83% of patients reported an improvement to functional class I or II. The majority of patients (98%) had no resting LVOT gradient. Long-term survival was excellent, with 98+/-1% survival at 1 year, 95+/-1% at 5 years, and 83+/-3% at 10 years after myectomy. Multivariable Cox regression analysis identified 5 predictors of overall mortality: (1) age > or =50 years at surgery (hazard ratio [HR] 2.8, 95% CI 1.5 to 5.1, P=0.001), (2) female gender (HR 2.5, 95% CI 1.5 to 4.3, P=0.0009), (3) history of preoperative atrial fibrillation (HR 2.2, 95% CI 1.2 to 4.0, P=0.008), (4) concomitant CABG (HR 3.7, 95% CI 1.7 to 8.2, P=0.001), and (5) preoperative left atrial diameter > or =46 mm (HR 2.9, 95% CI 1.6 to 5.4, P=0.0008). Significant predictors of late major cardiovascular events found on multivariable analysis were (1) female gender (HR 3.3, 95% CI 2.0 to 5.4, P<0.0001), (2) history of preoperative atrial fibrillation (HR 1.9, 95% CI 1.1 to 3.3, P=0.02), and (3) preoperative left atrial diameter > or =46 mm (HR 2.5, 95% CI 1.5 to 4.3, P=0.0008).
CONCLUSIONS: Myectomy provides excellent relief for LVOT obstruction in patients with hypertrophic cardiomyopathy. Preoperative clinical and echocardiographic variables can predict long-term outcome after myectomy.

Entities:  

Mesh:

Year:  2005        PMID: 15824202     DOI: 10.1161/01.CIR.0000162460.36735.71

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  53 in total

Review 1.  Hypertrophic cardiomyopathy in childhood.

Authors:  Steven D Colan
Journal:  Heart Fail Clin       Date:  2010-10       Impact factor: 3.179

Review 2.  Management of hypertrophic cardiomyopathy.

Authors:  Paolo Spirito; Camillo Autore
Journal:  BMJ       Date:  2006-05-27

3.  Increasing evidence for the safety and efficacy of alcohol septal ablation during medium- and long-term follow-up.

Authors:  M Pauschinger; A Keren
Journal:  Clin Res Cardiol       Date:  2007-11-05       Impact factor: 5.460

Review 4.  Contemporary treatment of hypertrophic cardiomyopathy.

Authors:  Ali J Marian
Journal:  Tex Heart Inst J       Date:  2009

5.  Prognostic value of left atrial function by cardiovascular magnetic resonance feature tracking in hypertrophic cardiomyopathy.

Authors:  Rocio Hinojar; Jose Luis Zamorano; MªAngeles Fernández-Méndez; Amparo Esteban; Maria Plaza-Martin; Ariana González-Gómez; Alejandra Carbonell; Luis Miguel Rincón; Jose Julio Jiménez Nácher; Covadonga Fernández-Golfín
Journal:  Int J Cardiovasc Imaging       Date:  2019-01-31       Impact factor: 2.357

Review 6.  Review on sudden death risk reduction after septal reduction therapies in hypertrophic obstructive cardiomyopathy.

Authors:  Angelos G Rigopoulos; Muhammad Ali; Elena Abate; Marios Matiakis; Hannes Melnyk; Sophie Mavrogeni; Dionyssios Leftheriotis; Boris Bigalke; Michel Noutsias
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

7.  Surgery for hypertrophic cardiomyopathy.

Authors:  James J Wu; Michael Seco; Caroline Medi; Chris Semsarian; David R Richmond; Joseph A Dearani; Hartzell V Schaff; Michael J Byrom; Paul G Bannon
Journal:  Biophys Rev       Date:  2015-01-10

Review 8.  Current status and future perspectives on alcohol septal ablation for hypertrophic obstructive cardiomyopathy.

Authors:  Rami N Khouzam; Srihari S Naidu
Journal:  Curr Cardiol Rep       Date:  2014-05       Impact factor: 2.931

9.  Hypertrophic obstructive cardiomyopathy-the Leipzig experience.

Authors:  Jawad Khalil; Michael Kuehl; Pirose Davierwala; Friedrich Wilhelm Mohr; Martin Misfeld
Journal:  Ann Cardiothorac Surg       Date:  2017-07

10.  Isolated septal myectomy for hypertrophic obstructive cardiomyopathy: an update on the Toronto General Hospital experience.

Authors:  Rachel D Vanderlaan; Anna Woo; Anthony Ralph-Edwards
Journal:  Ann Cardiothorac Surg       Date:  2017-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.